ClinicalTrials.gg
CompletedNCT07349394Updated Apr 2, 2026

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

A Phase 1 interventional study of VNZ/TEZ/D-IVA and Rosuvastatin in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated — 3 open to participants now, 8 under way, 5 of them phase 3. Cystic Fibrosis · Vertex Pharmaceuticals Incorporated.

Enrollment
105th of 116
18 · median 73
Started
2026
with 2 others
Phase 1
28 of 125
2 open now
Registered
123rd of 125
by date

Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 105th largest by enrollment of the 116 interventional ones that give a count, is one of 3 that started in 2026, is one of 28 in phase 1, and was the 123rd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

3 of the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.

Read the detailed description

The study is being conducted to evaluate the effect of multiple doses of VNZ/TEZ/D-IVA on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin in healthy participants.

Note: This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR11.60and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24and11.44.).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 32.0 kilogram per meter square (Kg/m\^2), both inclusive
  • A total body weight greater than (>)50 kg

Key Exclusion Criteria:

  • History of febrile illness within 5 days before the first dose of study drug
  • Any condition possibly affecting drug absorption
  • Female participants who are pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of the study drug
  • Male participants with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of the study drug

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    VNZ/TEZ/D-IVA and Rosuvastatin

    Rosuvastatin will be administered to participants as a single oral dose on Day 1 and then co-administered with VNZ/TEZ/D-IVA on Day 18.VNZ/TEZ/D-IVA dose will be administered once daily (qd) from Day 5 to Day 22.

    Drug: VNZ/TEZ/D-IVA · Drug: Rosuvastatin

Interventions

  • DrugVNZ/TEZ/D-IVA

    Fixed-dose combination (FDC) Tablet for oral administration.

    Also known as: Vanzacaftor/Tezacaftor/Deutivacaftor, VX-121/VX-661/VX-561, VX-121/VX-661/CTP-656

  • DrugRosuvastatin

    Tablet for oral administration.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) of Rosuvastatin in the Absence and Presence of VNZ/TEZ/D-IVA

    Time frame: Day 1 up to Day 23

  2. Area Under the Concentration Time-curve (AUC) of Rosuvastatin in the Absence and Presence of VNZ/TEZ/D-IVA

    Time frame: Day 1 up to Day 23

Secondary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Day 39

07

Study locations

1 site
  • Altasciences - Kansas City
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Feb 2026, 1 month.

Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 1 month is below that.

Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2026
First posted
Jan 16, 2026
StartActual
Jan 12, 2026
Primary completionActual
Feb 28, 2026
CompletionActual
Mar 12, 2026
Last update
Apr 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07349394
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jan 12, 2026
Primary completion
Feb 28, 2026
Completion
Mar 12, 2026
Last update
Apr 2, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion